Baptista GHA

Language: Spanish
References: 19
Page: 102-105
PDF size: 87.03 Kb.

ABSTRACT

We showed a systematic review of literature, on a concrete clinical scene, that consists of establishing if the inhibitors of cycle-oxygenase 2 (coxib-2), represented by rofecoxib and celecoxib, present with the same characteristics that the other analgesic nonesteroidal (NSAIDs), to produce intestinal hemorrhage. The beneficial effects of the NSAIDs, are associate with the inhibition of the cox-2 whereas their adverse effects, are associate with the inhibition of the cox-1. The arguments in favor of the coxib-2 indicate that they are as effective as the NSAIDs, because they inhibit cox-2 that produces the pain and their secondary effects are smaller, because they do not inhibit the enzyme cycle-oxygenase-1 (cox-1). The inhibition of cox-1 is responsible for the gastrointestinal ulcers produced by the NSAIDs. The conventional NSAIDs inhibit so much the cox-1 as the cox-2, despite rofecoxib and celecoxib demonstrates a much greater inhibition of the cox-2 than of the cox-1. In a study with healthy volunteers, assigned during seven days with placebo, rofecoxib, ibuprofen or aspirin. One documented that in the endoscopic examination of stomach and duodenum, that the number of erosions or ulcers was lower for placebo or rofecoxib, that with ibuprofen and aspirin. Also, the coxib-2 has been demonstrated that show to minor prevalence of gastroduodenal ulcers, after 3-12 months of processing, when comparing themselves with other NSAIDs (12 versus 46 %, respectively). In spite of the information with favorable balance towards coxib-2, the amount of information on the effectiveness not yet is complete. As much in acute pain as chronic, coxibs has even to the conventional NSAIDs, which grants an added value to them is its capacity to cause smaller gastrointestinal bleed.

REFERENCES

1. Brookes P. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Brit J Rheumatol 1999; 38: 779-87.

2. Warner TD et al. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Nat Acad Sci 1999; 96: 7563-68.

3. Somasundaram S. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: A review and a hypothesis. Scand J Gastroenterol 1995; 30: 289-99.

4. Mahmud T et al. Nonsteroidal anti-inflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis & Rheumatism 1996; 39: 1998-2003.

5. Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Selbold IR, De Schepper P, Mehlisch DR, Gertz BI. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999; 65: 336-47.

6. Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME, Wilson FR, Harper SE. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999; 13: 761-67.

7. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, Bolognese J. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776-83.

8. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, Shahane A, Quan H, Bolognese J, Mortensen E. Comparison of the effect of rofecoxib (a cyclooxigenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis & Rheumatism 2000; 43: 370-77.

9. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Gels GS. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial. Mayo Clin Proc 1999; 74: 1095-05.

10. Emery P et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomized double-blind comparison. Lancet 1999; 354: 2106-11.

11. Simon LS et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA 1999; 282: 1921-28.

12. Langman MJ et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-38.

13. Beejay U, Wolfe MM. Cyclooxygenase 2 selective inhibitors: Panacea or flash in the pain? Gastroenterology 1999; 117: 1002-05.

14. Peterson WL, Cryer B. Cox-1-sparing NSAIDs - is the enthusiasm justified? JAMA 1999; 282: 1961-63.

15. Hawkey C. Cox-2 specific inhibitors. Lancet 1999; 353: 307-14.

16. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999; 26 (Supp 56): 18-24.

17. Wolfe MM et al. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. NEJM 1999; 340: 1888-99.

18. Tramer MM et al. Quantitative estimation of rare adverse events which follow a biological progression: A new model applied to chronic NSAID use. Pain 2000; 85: 169-82.

19. Blower AL, Brooks A, Fenn CG et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11: 283-91.